RAPT RAPT Therapeutics Inc.

20.61
+0.03  (+0%)
Previous Close 20.58
Open 19.87
52 Week Low 14.63
52 Week High 41.86
Market Cap $515,435,634
Shares 25,009,007
Float 16,809,004
Enterprise Value $403,175,364
Volume 69,535
Av. Daily Volume 147,031
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
RPT193
Atopic dermatitis
Phase 1b
Phase 1b
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
FLX475
Advanced Cancer
Phase 1/2
Phase 1/2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. SOUTH SAN FRANCISCO, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2021.

    "Our oncology and inflammation programs continue to make excellent progress," said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. "We recently reported preclinical data at the AACR Annual Meeting that show anti-tumor potential of targeting and inhibiting CCR4 in combination with CAR-T therapy, as well…

    SOUTH SAN FRANCISCO, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2021.

    "Our oncology and inflammation programs continue to make excellent progress," said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. "We recently reported preclinical data at the AACR Annual Meeting that show anti-tumor potential of targeting and inhibiting CCR4 in combination with CAR-T therapy, as well as the promise of exciting next-generation immuno-oncology targets, such as HPK1. In March, we completed enrollment in our Phase 1b trial of RPT193, our lead inflammatory disease drug candidate, in patients with atopic dermatitis. We look forward to reporting top line results this quarter."

    Financial Results for the First Quarter Ended March 31, 2021

    Net loss for the first quarter of 2021 was $16.5 million, compared to $13.1 million for the first quarter of 2020.

    Research and development expenses for the first quarter of 2021 were $13.8 million, compared to $10.7 million for the same period in 2020. This increase was primarily due to increased clinical trial costs for FLX475 and RPT193, increased personnel costs and stock-based compensation expense and an increase in facilities costs, offset by a decrease in laboratory supplies spend.

    General and administrative expenses for the first quarter of 2021 were $4.0 million, compared to $3.3 million for the same period of 2020. The increase was primarily due to increases in stock-based compensation expense, insurance expense and personnel costs.

    As of March 31, 2021, the Company had cash and cash equivalents and marketable securities of $98.4 million.

    About RAPT Therapeutics, Inc.

    RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

    Forward-Looking Statements

    This press release contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the progress of RAPT's oncology and inflammation programs and the timing of top line results from the Phase 1b trial of RPT193. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPT's Form 10-Q filed with the Securities and Exchange Commission on May 11, 2021 and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements.

    RAPT Media Contact:

    Aljanae Reynolds

    RAPT Investor Contact:

    Sylvia Wheeler

    RAPT THERAPEUTICS INC.
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
    (In thousands, except share per share data)
    (Unaudited)
        
     Three Months Ended
     March 31,
      2021   2020 
    Revenue$1,222  $935 
    Operating expenses:   
    Research and development 13,771   10,683 
    General and administrative 4,012   3,289 
    Total operating expenses 17,783   13,972 
    Loss from operations (16,561)  (13,037)
    Other income, net 47   135 
    Net loss before taxes (16,514)  (12,902)
    Provision for income taxes    237 
    Net loss$(16,514) $(13,139)
    Other comprehensive income (loss):   
    Foreign currency translation adjustment 38   204 
    Unrealized loss on marketable securities (50)  (217)
    Total comprehensive loss$(16,526) $(13,152)
    Net loss per share, basic and diluted$(0.66) $(0.56)
    Weighted average number of shares used in computing net loss per share, basic and diluted 24,844,946   23,266,063 
            



    RAPT THERAPEUTICS, INC. 
    CONDENSED CONSOLIDATED BALANCE SHEETS 
    (In thousands) 
         
      March 31, December 31,
       2021   2020 
    Assets  (Unaudited)    (1)  
    Current assets:    
    Cash and cash equivalents $24,720  $24,918 
    Marketable securities  73,686   86,592 
    Prepaid expenses and other current assets  4,200   4,088 
    Total current assets  102,606   115,598 
    Property and equipment, net  2,929   2,982 
    Other assets  389   389 
    Total assets $105,924  $118,969 
    Liabilities and stockholders' equity    
    Current liabilities:    
    Accounts payable $3,131  $2,383 
    Accrued expenses  4,539   4,935 
    Deferred revenue, current  3,135   4,096 
    Other current liabilities  338   328 
    Total current liabilities  11,143   11,742 
    Deferred rent, net of current portion  2,157   2,185 
    Deferred revenue, non-current  983   863 
    Total liabilities  14,283   14,790 
    Commitments    
    Stockholders' equity:    
    Preferred stock      
    Common stock  2   2 
    Additional paid-in capital  323,184   319,196 
    Accumulated other comprehensive loss  (189)  (177)
    Accumulated deficit  (231,356)  (214,842)
    Total stockholders' equity  91,641   104,179 
    Total liabilities and stockholders' equity $105,924  $118,969 
         
    (1) The condensed consolidated balance sheet for December 31, 2020 has been derived from audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020
         


    Primary Logo

    View Full Article Hide Full Article
  2. SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced enrollment has been completed in its Phase 1b clinical trial of RPT193 in patients with moderate to severe atopic dermatitis (AD). The Company expects treatment follow up and data compilation to be completed in time for top line results to be reported in the first half of 2021.

    "We look forward to reporting top line data from this trial of RPT193 in atopic dermatitis, which could serve as initial proof…

    SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced enrollment has been completed in its Phase 1b clinical trial of RPT193 in patients with moderate to severe atopic dermatitis (AD). The Company expects treatment follow up and data compilation to be completed in time for top line results to be reported in the first half of 2021.

    "We look forward to reporting top line data from this trial of RPT193 in atopic dermatitis, which could serve as initial proof of concept in AD and a wide range of inflammatory diseases," said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics. "We believe an encouraging outcome in this Phase 1b trial would be if RPT193 shows a clear benefit compared to placebo in at least one key clinical or patient-reported endpoint. Evidence of efficacy, combined with once-daily oral convenience and a favorable safety profile, would be attractive in this patient population. This is an exciting time for RAPT as our CCR4 antagonist platform may potentially demonstrate broad clinical utility in both oncology and inflammation."



    RAPT's Phase 1b study is part of a first-in-human Phase 1a/1b trial of RPT193. The Phase 1b portion of the trial is a randomized, double-blind, placebo-controlled study in patients with moderate to severe AD. The study is being conducted at multiple sites in the United States and has enrolled 31 patients. The primary endpoint of the Phase 1b study is safety. Secondary and exploratory endpoints include pharmacokinetics, biomarkers and clinical efficacy as evaluated by multiple measurements, including the Eczema Area and Severity Index (EASI) and pruritis Numerical Rating Scale (NRS). The Phase 1b trial was not powered to achieve statistical significance for any particular endpoint.

    The Phase 1a portion of the Phase 1a/1b trial was a standard single and multiple dose escalation study in healthy volunteers. The data from the Phase 1a study demonstrated pharmacokinetics and pharmacodynamics that support once-daily oral dosing with RPT193, and blinded safety data supported initiation of the Phase 1b portion of the trial. Preclinical studies of RPT193 have demonstrated its ability to block the migration of mouse and human Th2 cells in vitro as well as inhibit inflammation in models of atopic dermatitis and asthma.

    About RPT193

    RPT193 is a small molecule oral therapy in development for the treatment of atopic dermatitis and other inflammatory diseases. RPT193 is designed to selectively inhibit the migration of Th2 cells into inflamed tissues by blocking CCR4, a receptor highly expressed on Th2 cells. In allergic inflammatory diseases such as AD, chemokines recruit Th2 cells via CCR4 into inflamed tissues, where the Th2 cells secrete proteins known to drive the inflammatory response. The role of Th2 cells has been clinically validated by injectable biologics targeting this pathway. Patients with atopic dermatitis express higher levels of CCR4 ligands compared with healthy humans; these ligands also correlate with the severity of disease. RAPT believes that by inhibiting CCR4, RPT193 has the potential to bring therapeutic benefit to patients across a broad spectrum of inflammatory diseases, including atopic dermatitis, asthma, chronic urticaria, allergic rhinitis, chronic rhinosinusitis and eosinophilic esophagitis.

    About Atopic Dermatitis

    Atopic dermatitis is a chronic, inflammatory skin disease characterized by skin barrier disruption and immune dysregulation. Patients with AD have chronically inflamed skin lesions that can cause debilitating pruritus (itch), which can severely impair quality of life. While there are marketed injectable products for the treatment of AD, RAPT believes RPT193, if approved, could fill an unmet medical need for the treatment of inflammatory disorders with the convenience of once daily oral dosing.

    About RAPT Therapeutics, Inc.

    RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

    Forward-Looking Statements

    This press release contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the timing of the Phase 1b clinical trial of RPT193, interpretations of possible outcomes from that trial and the potential of RPT193 to treat atopic dermatitis or other inflammatory diseases. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPT's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2021 and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements.

    Investor Contact:

    Sylvia Wheeler



    Media Contact:

    Aljanae Reynolds



    Primary Logo

    View Full Article Hide Full Article
  3. SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the fourth quarter and year ended December 31, 2020.

    "In 2020, we achieved important advancements in clinical development for our two lead programs: FLX475 in oncology and RPT193 in inflammatory diseases," said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. "In November, we reported early evidence of clinical activity for FLX475, both as monotherapy…

    SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the fourth quarter and year ended December 31, 2020.

    "In 2020, we achieved important advancements in clinical development for our two lead programs: FLX475 in oncology and RPT193 in inflammatory diseases," said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. "In November, we reported early evidence of clinical activity for FLX475, both as monotherapy and in combination with pembrolizumab, in multiple tumor types. These data helped us determine advancement of several cohorts in our multi-cohort, multi-indication Phase 1/2 trial. For RPT193, we continued enrolling our Phase 1b study of RPT193 in atopic dermatitis over the course of 2020 despite a brief pause early in the year because of the pandemic. Today, we are well positioned for key data readouts for both RPT193 and FLX475. We plan to report on the Phase 1b trial for RPT193 in the first half of 2021 and provide an update in the second half of 2021 on additional data generated with FLX475 in multiple cohorts that have sufficiently matured."

    Financial Results for the Fourth Quarter and Year Ended December 31, 2020

    Fourth Quarter Ended December 31, 2020

    Net loss for the fourth quarter of 2020 was $12.7 million, compared to $13.2 million for the fourth quarter of 2019.

    Research and development expenses for the fourth quarter of 2020 were $10.9 million, compared to $10.2 million for the same period in 2019 due to increased clinical trial costs for FLX475 and RPT193, increased personnel costs and stock-based compensation expense and an increase in preclinical program costs, offset by a decrease in laboratory supplies spend.

    General and administrative expenses for the fourth quarter of 2020 were $3.5 million, compared to $2.6 million for the same period of 2019. The increase was primarily due to increases in stock-based compensation expense, personnel costs, legal and accounting fees and insurance expense, offset by a decrease in consulting costs.

    Year Ended December 31, 2020

    Net loss for the year ended December 31, 2020 was $52.9 million, compared to $43.0 million for the same period in 2019.

    Research and development expenses for the year ended December 31, 2020 were $45.5 million, compared to $34.9 million for the same period in 2019. The increase was primarily due to an increase in clinical trial costs relating to FLX475 and RPT193, increased preclinical program costs as well as increases in stock-based compensation and personnel expenses, offset by decreases in lab supplies and travel costs.

    General and administrative expenses for the year ended December 31, 2020 were $12.8 million, compared to $8.7 million for the same period of 2019. The increase in general and administrative expenses was primarily due to increases in stock-based compensation expense, personnel costs and costs associated with our public company status, offset by a decrease in professional fee and travel costs.

    As of December 31, 2020, the Company had cash and cash equivalents and marketable securities of $111.5 million.

    About RAPT Therapeutics, Inc.

    RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

    Forward-Looking Statements

    This press release contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about clinical development progress and the timing of results from clinical trials of FLX475 and RPT193. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPT's Form 10-K filed with the Securities and Exchange Commission on March 11, 2021 and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements.

    RAPT Media Contact:

    Aljanae Reynolds

    RAPT Investor Contact:

    Sylvia Wheeler

     
    RAPT THERAPEUTICS, INC.
    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
    (In thousands, except share and per share data)
             
      Three Months Ended Year Ended
      December 31, December 31,
       2020   2019   2020   2019 
    Revenue $1,302  $  $5,042  $ 
    Operating expenses:        
    Research and development  10,904   10,190   45,485   34,910 
    General and administrative  3,483   2,625   12,771   8,719 
    Total operating expenses  14,387   12,815   58,256   43,629 
    Loss from operations  (13,085)  (12,815)  (53,214)  (43,629)
    Other income, net  549   259   1,312   1,292 
    Net loss before taxes  (12,536)  (12,556)  (51,902)  (42,337)
    Provision for income taxes  199   660   990   660 
    Net loss $(12,735) $(13,216) $(52,892) $(42,997)
    Other comprehensive income (loss):        
    Foreign currency translation adjustment  (184)  7   (249)  24 
    Unrealized gain on marketable securities  (67)     52    
    Total comprehensive loss $(12,986) $(13,209) $(53,089) $(42,973)
    Net loss per share, basic and diluted $(0.52) $(0.87) $(2.19) $(9.89)
    Weighted average number of shares used in computing net loss per share, basic and diluted  24,582,616   15,255,118   24,134,305   4,346,400 



     
    RAPT THERAPEUTICS, INC.
    CONSOLIDATED BALANCE SHEETS
    (In thousands)
         
      December 31,
       2020   2019 
    Assets    
    Current assets:    
    Cash and cash equivalents $24,918  $77,383 
    Marketable securities  86,592    
    Prepaid expenses and other current assets  4,088   3,123 
    Total current assets  115,598   80,506 
    Property and equipment, net  2,982   3,707 
    Other assets  389   389 
    Total assets $118,969  $84,602 
    Liabilities and stockholders' equity    
    Current liabilities:    
    Accounts payable $2,383  $1,143 
    Accrued expenses  4,935   3,642 
    Deferred revenue, current  4,096   4,000 
    Other current liabilities  328   471 
    Total current liabilities  11,742   9,256 
    Deferred revenue, net of current portion  863    
    Deferred rent, net of current portion  2,185   2,225 
    Total liabilities  14,790   11,481 
    Commitments    
    Stockholders' equity:    
    Preferred stock, $0.0001 par value: 50,000,000 shares authorized; no shares issued and outstanding at December 31, 2020 and 2019      
    Common stock, $0.0001 par value; 500,000,000 shares authorized; 24,773,361 and 21,833,037 shares issued and outstanding at December 31, 2020 and 2019, respectively  2   2 
    Additional paid-in capital  319,196   235,049 
    Accumulated other comprehensive income (loss)  (177)  20 
    Accumulated deficit  (214,842)  (161,950)
    Total stockholders' equity  104,179   73,121 
    Total liabilities and stockholders' equity $118,969  $84,602 



    Primary Logo

    View Full Article Hide Full Article
    • Tumor model data shows potential of CCR4 antagonist to alter immunosuppressive tumor microenvironment to improve CAR T-cell therapy in solid tumors

    • Small-molecule HPK1 inhibitors enhance antitumor immunity in tumor model

    • Inhibiting GCN2 stress kinase shows potential to restore immunity in tumor microenvironment

    SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced several upcoming preclinical poster presentations at the American Association for Cancer Research…

    • Tumor model data shows potential of CCR4 antagonist to alter immunosuppressive tumor microenvironment to improve CAR T-cell therapy in solid tumors



    • Small-molecule HPK1 inhibitors enhance antitumor immunity in tumor model



    • Inhibiting GCN2 stress kinase shows potential to restore immunity in tumor microenvironment

    SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced several upcoming preclinical poster presentations at the American Association for Cancer Research annual meeting demonstrating promise and potential of its pipeline of anti-cancer agents.

    "Our posters at AACR reflect our continued exploration into the role of the immune system in cancer and the potential of immunology-based therapies to address certain challenges in oncology," said Dirk Brockstedt, Ph.D., Chief Scientific Officer of RAPT. "Specifically, the role and importance of CCR4 inhibition will be highlighted and continue to support the early clinical data we have observed with FLX475, our CCR4 inhibitor being evaluated in a Phase 1/2 trial in multiple tumors. In addition, we will also present preclinical data on two exciting next-generation immune-oncology targets, HPK1 and GCN2, which show that orally available inhibitors elicit potent antitumor immune responses in a variety of cancer models."

    Summaries of the studies to be presented:

    Poster: 1585

    Title: T-regulatory cells impair CAR T-cell-mediated antitumor activity in a murine solid tumor model

    Session Title: Combination Immunotherapies

    Chimeric antigen receptor (CAR) T cell immunotherapy has had only modest success in solid malignancies due in part to tumor antigen heterogeneity and the immunosuppressive tumor microenvironment, which is believed to be at least in part due to immunosuppressive regulatory T cells (Treg). Treg express CCR4 and migrate toward CCL17 and CCL22 which are frequently upregulated in a subset of tumors or increased following immunotherapy. In a murine mesothelioma model, a combination of CAR- T-cells plus CCR4 antagonist significantly slowed tumor growth and significantly improved survival compared to untreated control. Furthermore, enhanced antitumor activity was observed with the combination of CAR T cells and CCR4 antagonist compared to either monotherapy, with 4/9 mice treated with the combination becoming tumor free and experienced significantly increased survival.

    Poster: 1646

    Title: Development of small-molecule HPK1 inhibitors to unleash tumor-specific T cell responses

    Session Title: Immune Checkpoints

    Hematopoietic progenitor kinase 1 (HPK1) is an intracellular protein kinase that is associated with inhibition of critical immune T cell signaling and proliferation important for mounting an effective immune response against tumor cells.  RAPT's small-molecule compounds demonstrated potent inhibition of HPK1 in biochemical assays, reduction of levels of phosphorylated SLP76 and concomitant increase in IL-2 production.  In addition, the Company's HPK1 inhibitors enhanced cytokine production of human and mouse primary T cells above that observed with T-cell receptor activation alone. Notably, treatment of mice with an orally available HPK1 inhibitor resulted in increased activation of antigen-specific CD8 T-cells and decreased tumor growth as monotherapies and in combination with clinically relevant checkpoint inhibitor antibodies. 

    Poster: 3153

    Title: Targeting the stress response kinase GCN2 to restore immunity in the tumor microenvironment

    Session Title: Tumor Microenvironment

    Recent advances in cancer metabolism suggest that targeting amino acid metabolism represents a promising strategy for the development of novel therapeutic agents. Tumor, stromal and myeloid-derived suppressor cells (MDSC) within the tumor microenvironment (TME) create a nutrient-poor environment that inhibits immune function and support tumor growth. GCN2 (general control nonderepressible 2), a stress response kinase, plays a key role in maintaining cellular homeostasis under a wide range of stressors, leading to T cell anergy, apoptosis, enhanced MDSC-dependent immune suppression and tumor cell survival. The treatment of nutrient-deprived T cells in vitro with a GCN2 inhibitor enhanced CD4 and CD8 T-cell proliferation and effector functions. The GCN2 inhibitor also reversed T cell suppression mediated by MDSCs derived from healthy donors or cancer patients. In syngeneic mouse tumor models, oral administration of a GCN2 inhibitor showed impressive drug-target engagement and potently inhibited GCN2 kinase in the tumor microenvironment. Furthermore, the GCN2 inhibitor as a single agent and in combination with checkpoint inhibitors and angiogenesis inhibitor (anti-VEGFR) delayed tumor growth in renal cell carcinoma and lung cancer syngeneic tumor models.

    About RAPT Therapeutics, Inc.

    RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

    Forward-Looking Statements

    This press release contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the significance of early results from the Phase 1/2 clinical trials of FLX475 and preclinical studies of HPK1 and GCN2, and statements about the potential of CCR4, HPK1 and GCN2 to enhance antitumor activity. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPT's most recent Form 10-Q filed with the Securities and Exchange Commission and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements.

    Investor Contact:

    Sylvia Wheeler

    wheelhouselsa.com

    Media Contact:

    Aljanae Reynolds



    Primary Logo

    View Full Article Hide Full Article
  4. SOUTH SAN FRANCISCO, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will participate in the following investor conferences in March:

    • H.C. Wainwright Global Life Sciences Conference – A recording of the company presentation will be available Tuesday, March 9, 2021 at 7:00 am Eastern Time.

    • 33rd Annual Roth Conference – Featured panelist on "Novel Immuno-Oncology Targets That Could Improve Clinical…

    SOUTH SAN FRANCISCO, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will participate in the following investor conferences in March:

    • H.C. Wainwright Global Life Sciences Conference – A recording of the company presentation will be available Tuesday, March 9, 2021 at 7:00 am Eastern Time.



    • 33rd Annual Roth Conference – Featured panelist on "Novel Immuno-Oncology Targets That Could Improve Clinical Outcomes" panel March 15, 2021 at 2:00 pm Eastern Time.

    To access the live panel webcast or subsequent archived recording of the panel or company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

    About RAPT Therapeutics, Inc.

    RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

    Investor Contact:

    Sylvia Wheeler

    Media Contact:

    Aljanae Reynolds



    Primary Logo

    View Full Article Hide Full Article
View All RAPT Therapeutics Inc. News